We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: 1 Route for ANDA Label Revisions Sans Reference Drug
FDA: 1 Route for ANDA Label Revisions Sans Reference Drug
The FDA is advising generic drugmakers looking to revise their labels without the fallback of a reference product that they have only one route: supplemental submissions.